<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150383</url>
  </required_header>
  <id_info>
    <org_study_id>UISM-4</org_study_id>
    <nct_id>NCT01150383</nct_id>
  </id_info>
  <brief_title>SCOPE-Study: Salzburg Chronic Obstructive Pulmonary Disease- Exercise and Oxygen Study</brief_title>
  <acronym>SCOPE</acronym>
  <official_title>The Effect of Supplemental Oxygen During Physical Exercise Training on Exercise Capacity in COPD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paracelsus Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paracelsus Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is number four of the leading causes of death in
      the USA and Europe. Moreover, among the top five causes of death, this disease is the only
      one with increasing mortality rates. Physical training has become an evidence based
      therapeutic intervention in these patients.

      In this study the investigators aim to establish if supplemental oxygen during strength and
      endurance training improves exercise tolerance. Furthermore, the investigators want to
      research, if supplemental oxygen has the ability to increase training intensity, which would
      lead to a greater training effect with respect to respiratory, vascular, inflammatory and
      anthropometric parameters, as well as quality of life.

      SCOPE is a prospective, randomized, double-blinded, controlled, cross-over trial. The
      investigators aim to enroll 40 patients suffering from COPD aged &gt;30 years. Inclusion
      criteria are FEV1 30-60%, and PO2 at rest &gt;55 mmHg. At baseline, patients will undergo
      pre-tests including pulmonary, exercise physiological and medical investigations. Prior to
      the exercise training, an intervention-free control period with usual care is planned. This
      will be followed by 2 x 6 weeks with physical training (ergometer based endurance training
      and strength training, using weight lifting machines) with either supplemental oxygen or
      usual room air (e.g.: first 6 weeks of exercise with oxygen supplementation followed by 6
      weeks of room air). After the initial control period and between these two exercise periods,
      patients will be tested as described in pre-tests, and at the end of the second exercise
      training period. In addition, the investigators will assess changes in lung function and
      symptomatic dyspnoea, as well as in quality of life (St. George's Respiratory Questionnaire).

      Within this study, the investigators hope to improve rehabilitation programs for COPD
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise capacity (Watts/kg)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To investigate the effectiveness of physical training in COPD- patients comparing a 6 week period of exercise under oxygen supplementation with a 6 week period of exercise under &quot;room air supplementation&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured by St. George Respiratory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen uptake (VO2-max)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measurement of spiroergometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate, blood pressure and exercise capacity at lactate-thresholds 2,3 and 4.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measurement of ergometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BODE-index</measure>
    <time_frame>6 weeks</time_frame>
    <description>The BODE index is a simple multidimensional grading system for COPD-patients which considers body-mass index, degree of airflow obstruction (FEV1) and dyspnea (BORG scale), and exercise capacity, which will be measured by the six-minute-walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>6-minute-walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured by BORG-scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>6 weeks</time_frame>
    <description>Body composition/muscle volume will be measured using magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters of inflammation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Inflammatory changes will be assessed via blood test analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular changes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Vascular changes will be assessed via blood test analysis as well as analysis of endothelial function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ten repetition maximum</measure>
    <time_frame>6 weeks</time_frame>
    <description>The ten repetition maximum (10-RM) is a measure of the maximal weight a subject can lift 10 times.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>group RO (Room air / Oxygen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group OR (Oxygen / Room air)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical exercise training with supplemental oxygen</intervention_name>
    <description>Prior to the exercise training, an intervention-free control period with usual care is planned.
Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.
After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above).</description>
    <arm_group_label>group OR (Oxygen / Room air)</arm_group_label>
    <other_name>training</other_name>
    <other_name>physical training</other_name>
    <other_name>exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical exercise training with &quot;room air supplementation&quot;</intervention_name>
    <description>Prior to the exercise training, an intervention-free control period with usual care is planned.
Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.
After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above).</description>
    <arm_group_label>group RO (Room air / Oxygen)</arm_group_label>
    <other_name>training</other_name>
    <other_name>physical training</other_name>
    <other_name>exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD with FEV1 pred. 30 to 60%, PO2 at rest &gt; 55 mmHg and PCO2 &lt; 45 mm Hg

          -  age: &gt; 30 years

        Exclusion Criteria:

          -  Musculoskeletal disease, which prohibits training

          -  Relevant neoplastic disease with cachexia

          -  Expected non compliance with the study protocol due to drug and alcohol abuse

          -  Coronary heart disease defined by angina pectoris or relevant ST-changes during
             exercise or myocardial infarction in the last 6 months

          -  Left ventricular ejection fraction &lt; 40 %

          -  Renal insufficiency with creatinine &gt; 2 mmol/liter

          -  Symptomatic intermittent claudication or peripheral neuropathy

          -  Anaemia &lt; 10 mg/dl or red blood count &lt; 3 Mio/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Niebauer, MD, PhD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/copdchronicobstructivepulmonarydisease.html</url>
  </link>
  <link>
    <url>http://www.salk.at/</url>
  </link>
  <reference>
    <citation>Vogiatzis I, Athanasopoulos D, Stratakos G, Garagouni C, Koutsoukou A, Boushel R, Roussos C, Zakynthinos S. Exercise-induced skeletal muscle deoxygenation in O-supplemented COPD patients. Scand J Med Sci Sports. 2009 Jun;19(3):364-72. doi: 10.1111/j.1600-0838.2008.00808.x. Epub 2009 May 19.</citation>
    <PMID>18492053</PMID>
  </reference>
  <reference>
    <citation>Nonoyama ML, Brooks D, Lacasse Y, Guyatt GH, Goldstein RS. Oxygen therapy during exercise training in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005372. Review.</citation>
    <PMID>17443585</PMID>
  </reference>
  <reference>
    <citation>ZuWallack RL. The roles of bronchodilators, supplemental oxygen, and ventilatory assistance in the pulmonary rehabilitation of patients with chronic obstructive pulmonary disease. Respir Care. 2008 Sep;53(9):1190-5.</citation>
    <PMID>18718038</PMID>
  </reference>
  <reference>
    <citation>Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009 Feb;33(2):262-72. doi: 10.1183/09031936.00024608. Epub 2008 Nov 14. Erratum in: Eur Respir J. 2010 Aug;36(2):462.</citation>
    <PMID>19010994</PMID>
  </reference>
  <reference>
    <citation>Puhan MA, Sch√ºnemann HJ, Frey M, Scharplatz M, Bachmann LM. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax. 2005 May;60(5):367-75. Review.</citation>
    <PMID>15860711</PMID>
  </reference>
  <reference>
    <citation>Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009 Mar 26;360(13):1329-35. doi: 10.1056/NEJMct0804632. Review.</citation>
    <PMID>19321869</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Paracelsus Medical University</investigator_affiliation>
    <investigator_full_name>Prof. Josef Niebauer M.D., Ph.D., MBA</investigator_full_name>
    <investigator_title>Prim. Prof. MD, PhD, MBA</investigator_title>
  </responsible_party>
  <keyword>Lung Diseases, Obstructive</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiration Disorders</keyword>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive Lung Disease</keyword>
  <keyword>Chronic Obstructive Airway Disease</keyword>
  <keyword>Chronic Airflow Obstruction</keyword>
  <keyword>oxygen</keyword>
  <keyword>oxygen supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

